Managing anti-NMDA receptor encephalitis presents substantial challenges for neurologists and critical care specialists worldwide. While acute first-line immunotherapies often induce initial remission, disease relapses occur in nearly a quarter of patients. These recurrent neuroinflammatory episodes cause cumulative disability, persistent cognitive impairment, and heightened emotional stress for families. Clinicians have long sought an effective, well-tolerated maintenance regimen to secure sustained remission. The recently published LEARN trial offers robust, high-quality evidence supporting the role of long-term mycophenolate mofetil in preventing relapses and improving secondary neuropsychiatric outcomes.

Clinical Challenges in Managing Anti-NMDA Receptor Encephalitis

Anti-N-methyl-D-aspartate receptor encephalitis is a severe autoimmune neurological disorder driven by autoantibodies against the GluN1 subunit of NMDA receptors. Patients typically present with acute psychiatric disturbances, memory loss, seizures, movement disorders, and autonomic instability. Standard practice involves rapid induction with first-line immunotherapies such as high-dose intravenous methylprednisolone, intravenous immunoglobulin, or therapeutic plasma exchange. However, acute clearance of autoantibodies does not always extinguish prolonged immune activation. B cells and antibody-secreting plasma cells can persist within the central nervous system compartments. Consequently, clinicians frequently witness clinical relapse within the first two years of onset. Preventing these recurrent episodes remains vital because second episodes often prove more refractory to treatment. In low- and middle-income healthcare settings, frequent hospital admissions place immense financial strain on households. Therefore, establishing a reliable, affordable, and easily administered oral maintenance therapy addresses a critical clinical priority.

The LEARN Trial: Study Design and Patient Selection

The multicentre, open-label, blinded-endpoint randomised controlled LEARN trial addressed this critical therapeutic dilemma across four academic neurology centres in China. Investigators recruited 100 participants aged 14 and older presenting with acute anti-NMDA receptor encephalitis. Eligible participants presented to the hospital within two weeks of symptom onset and carried a modified Rankin Scale score of 2 or higher. The trial randomly allocated patients into two distinct treatment arms. The control arm received standard first-line immunotherapy alone, whereas the experimental arm received standard first-line therapy combined with oral mycophenolate mofetil. Investigators administered mycophenolate mofetil at a fixed dose of 0.5 grams twice daily for a continuous 24-month duration. Independent evaluators blinded to treatment allocation assessed neurological status, cognitive deficits, and overall disability. By combining rigorous prospective randomisation with blinded endpoint assessment, the investigators generated valuable Class II evidence to guide real-world practice.

Primary Outcomes: Significant Reduction in Disease Relapse

The primary outcomes of the trial centered on two key parameters: overall relapse rates and time to first disease relapse. The clinical results demonstrated striking advantages for the combination arm. Patients receiving maintenance mycophenolate mofetil experienced a significantly lower relapse rate of only 5.9 percent over the 24-month follow-up period. In contrast, patients receiving first-line treatment alone suffered a relapse rate of 26.5 percent. Statistical analysis confirmed this difference was highly significant, with a p-value of 0.006. Furthermore, Kaplan-Meier curves indicated that the time to first relapse was significantly prolonged in the mycophenolate mofetil group. These findings indicate that adjunctive antimetabolite therapy delivers durable immunosuppressive control beyond the initial acute crisis. By interrupting lymphocyte proliferation, the drug suppresses residual autoreactive clones. Consequently, sustained administration effectively shields recovering neural pathways from recurrent antibody-mediated attacks.

Secondary Neurological Outcomes and Symptom Relief

Beyond preventing relapses, the study evaluated crucial secondary functional and cognitive outcomes. Interestingly, overall functional disability measured by the modified Rankin Scale at 12 and 24 months showed no significant divergence between the two cohorts. However, the mycophenolate mofetil group demonstrated a superior early treatment response within four weeks, reaching 84.3 percent compared to 65.3 percent in the control arm. Moreover, patients taking maintenance therapy experienced markedly lower rates of disabling secondary symptoms. Specifically, participants reported fewer cognitive deficits, less debilitating fatigue, and reduced depressive symptoms. The maintenance cohort also displayed better seizure control during extended recovery. Because anti-NMDA receptor encephalitis frequently leaves subtle neuropsychiatric sequelae that hinder professional reintegration, these cognitive and emotional gains represent meaningful real-world benefits for recovering patients.

Safety Profile and Tolerability of Long-Term Maintenance

Safety and tolerability represent paramount considerations when prescribing an immunosuppressive agent for two full years. In the LEARN trial, oral mycophenolate mofetil demonstrated an encouraging, benign safety profile. Adverse events occurred with comparable frequencies between both groups, and the vast majority were mild to moderate in severity. Clinicians observed transient gastrointestinal disturbances, minor transaminase elevations, and non-severe viral upper respiratory tract infections. Importantly, no fatal infections, opportunistic fungal diseases, or severe anaphylactic reactions occurred throughout the two-year intervention. Because the trial employed a moderate maintenance dose of 1 gram total daily, patients tolerated the therapy without requiring frequent treatment discontinuations. These reassuring observations suggest that long-term maintenance is both safe and feasible, provided clinicians maintain routine monitoring of complete blood counts and hepatic function.

Translating Clinical Evidence into Practice in India

These findings hold profound practical implications for Indian healthcare settings. In India, managing autoimmune encephalitis involves striking a delicate balance between therapeutic efficacy, monitoring logistics, and long-term economic expenditure. While monoclonal antibodies such as rituximab remain valuable second-line options, their direct medication costs and parenteral administration requirements can strain family resources. In contrast, mycophenolate mofetil is widely accessible as a generic oral medication across Indian retail pharmacies. Its moderate cost, oral route, and manageable adverse effect profile make it an attractive maintenance solution for suburban and rural patients. Furthermore, treating a severe relapse in an intensive care unit costs substantially more than two years of oral maintenance. Incorporating early maintenance mycophenolate mofetil into regional management protocols offers clinicians a practical strategy to protect neurological recovery, prevent catastrophic relapses, and optimise overall healthcare expenditure.

Frequently Asked Questions

What is the recommended dose and duration of mycophenolate mofetil for encephalitis?

In the LEARN trial, investigators administered oral mycophenolate mofetil at 0.5 grams twice daily for 24 months. Clinicians should initiate therapy alongside acute first-line immunotherapy and maintain it continuously. Periodic laboratory monitoring of full blood counts and liver enzymes remains essential throughout the treatment period.

Does mycophenolate mofetil improve long-term functional scores at two years?

Interestingly, the trial found no statistically significant difference in modified Rankin Scale scores at 12 and 24 months. However, the therapy significantly improved early four-week response rates. It also reduced long-term neuropsychiatric complications, including persistent fatigue, cognitive impairment, depression, and recurrent seizure episodes.

Why is relapse prevention critical in patients recovering from encephalitis?

Disease relapses in autoimmune encephalitis can produce permanent axonal damage, secondary epilepsy, and worsening psychiatric deficits. Furthermore, relapses often demand prolonged intensive care and expensive rescue treatments. Preventing secondary episodes preserves cognitive function, eases financial burdens, and ensures durable neurological recovery for recovering individuals.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

Gong X et al. Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial. J Neurol Neurosurg Psychiatry. 2025 Sep 12. doi: 10.1136/jnnp-2024-335400. PMID: 40015729.
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165.
Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045-1057.